VYNE Therapeutics (NASDAQ:VYNE) Upgraded by Wall Street Zen to Sell Rating

VYNE Therapeutics (NASDAQ:VYNE) was upgraded by research analysts at Wall Street Zen to a “sell” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of VYNE Therapeutics in a research report on Wednesday, October 8th. Three research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and an average price target of $4.50.

VYNE Therapeutics Stock Up 0.2%

VYNE stock opened at $0.59 on Friday. VYNE Therapeutics has a twelve month low of $0.28 and a twelve month high of $4.30. The company has a market cap of $19.51 million, a P/E ratio of -0.75 and a beta of 1.99. The business’s fifty day moving average is $0.38 and its 200-day moving average is $0.60.

VYNE Therapeutics (NASDAQ:VYNE) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.02. VYNE Therapeutics had a negative return on equity of 80.84% and a negative net margin of 6,425.19%.The business had revenue of $0.17 million during the quarter, compared to analysts’ expectations of $0.13 million. Research analysts anticipate that VYNE Therapeutics will post -0.97 earnings per share for the current fiscal year.

Hedge Funds Weigh In On VYNE Therapeutics

Several institutional investors have recently modified their holdings of the business. Baker BROS. Advisors LP acquired a new position in shares of VYNE Therapeutics in the 3rd quarter valued at approximately $285,000. Shay Capital LLC acquired a new stake in VYNE Therapeutics during the 3rd quarter worth approximately $165,000. Two Sigma Investments LP bought a new position in VYNE Therapeutics in the third quarter valued at approximately $74,000. Boothbay Fund Management LLC acquired a new position in shares of VYNE Therapeutics in the second quarter valued at approximately $176,000. Finally, Adage Capital Partners GP L.L.C. boosted its holdings in shares of VYNE Therapeutics by 87.2% in the second quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock valued at $1,063,000 after buying an additional 300,000 shares during the period. Institutional investors own 83.78% of the company’s stock.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.